Aytu BioPharma (AYTU) Competitors $2.37 0.00 (0.00%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.35 -0.02 (-1.05%) As of 08/8/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. IVVD, ADAG, ADAP, VIRI, WHWK, VXRT, MGX, VTGN, ORMP, and ARTVShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Invivyd (IVVD), Adagene (ADAG), Adaptimmune Therapeutics (ADAP), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Vaxart (VXRT), Metagenomi (MGX), VistaGen Therapeutics (VTGN), Oramed Pharmaceuticals (ORMP), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors Invivyd Adagene Adaptimmune Therapeutics Virios Therapeutics Whitehawk Therapeutics Vaxart Metagenomi VistaGen Therapeutics Oramed Pharmaceuticals Artiva Biotherapeutics Aytu BioPharma (NASDAQ:AYTU) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Is AYTU or IVVD more profitable? Aytu BioPharma has a net margin of 2.37% compared to Invivyd's net margin of -389.01%. Aytu BioPharma's return on equity of 3.51% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Aytu BioPharma2.37% 3.51% 0.91% Invivyd -389.01%-165.24%-99.71% Does the media favor AYTU or IVVD? In the previous week, Invivyd had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for Invivyd and 0 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.00 equaled Invivyd'saverage media sentiment score. Company Overall Sentiment Aytu BioPharma Neutral Invivyd Neutral Which has more volatility and risk, AYTU or IVVD? Aytu BioPharma has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Which has higher valuation and earnings, AYTU or IVVD? Aytu BioPharma has higher revenue and earnings than Invivyd. Aytu BioPharma is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAytu BioPharma$81M0.26-$15.84M-$0.72-3.29Invivyd$25.38M3.77-$169.93M-$1.20-0.66 Do insiders & institutionals have more ownership in AYTU or IVVD? 33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 3.6% of Aytu BioPharma shares are held by company insiders. Comparatively, 25.4% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer AYTU or IVVD? Aytu BioPharma currently has a consensus target price of $10.00, suggesting a potential upside of 321.94%. Invivyd has a consensus target price of $5.85, suggesting a potential upside of 633.17%. Given Invivyd's stronger consensus rating and higher probable upside, analysts plainly believe Invivyd is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryInvivyd beats Aytu BioPharma on 10 of the 16 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.27M$2.99B$5.49B$9.72BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-3.2917.1130.0524.70Price / Sales0.26331.80460.24101.80Price / CashN/A40.7324.8428.01Price / Book0.518.888.525.76Net Income-$15.84M-$54.75M$3.27B$267.05M7 Day Performance-1.25%0.01%6.13%5.08%1 Month Performance3.49%0.64%0.07%0.61%1 Year Performance-0.84%8.71%36.43%22.83% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma3.1705 of 5 stars$2.37flat$10.00+321.9%-0.8%$21.27M$81M-3.29160IVVDInvivyd3.1443 of 5 stars$0.84+6.7%$5.85+598.7%-22.5%$94.17M$25.38M-0.70100News CoverageUpcoming EarningsADAGAdagene2.9303 of 5 stars$1.99-0.2%$8.00+302.8%-10.3%$93.75M$100K0.00260News CoverageAnalyst ForecastAnalyst RevisionADAPAdaptimmune Therapeutics2.769 of 5 stars$0.10-71.2%$1.35+1,251.7%-92.2%$91.95M$178.03M-0.37490Upcoming EarningsHigh Trading VolumeVIRIVirios Therapeutics0.1101 of 5 stars$4.77+0.8%$5.00+4.8%+2,702.3%$91.86MN/A-17.675News CoverageWHWKWhitehawk TherapeuticsN/A$1.81-7.2%N/AN/A$91.86M$25.98M11.3140News CoveragePositive NewsEarnings ReportAnalyst DowngradeVXRTVaxart2.7071 of 5 stars$0.41+1.3%$3.00+640.7%-34.5%$91.57M$47.40M-1.50120News CoverageUpcoming EarningsMGXMetagenomi2.5906 of 5 stars$2.52+3.7%$13.00+415.9%-33.3%$90.84M$45.26M-1.19236News CoverageUpcoming EarningsVTGNVistaGen Therapeutics1.2924 of 5 stars$3.19+3.6%N/A-12.9%$89.81M$490K-1.9240News CoverageEarnings ReportUpcoming EarningsGap UpHigh Trading VolumeORMPOramed Pharmaceuticals0.3058 of 5 stars$2.21+2.3%N/A-10.7%$88.22M$1.34M-5.0210News CoveragePositive NewsUpcoming EarningsARTVArtiva Biotherapeutics2.3541 of 5 stars$2.96-17.8%$17.80+501.4%-75.6%$87.71M$250K0.0081Earnings ReportAnalyst Revision Related Companies and Tools Related Companies Invivyd Alternatives Adagene Alternatives Adaptimmune Therapeutics Alternatives Virios Therapeutics Alternatives Whitehawk Therapeutics Alternatives Vaxart Alternatives Metagenomi Alternatives VistaGen Therapeutics Alternatives Oramed Pharmaceuticals Alternatives Artiva Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AYTU Stock Alerts